Zenocutuzumab

N/A

Report date: 2026/05/12 15:55:38

Base Information

Drug NameZenocutuzumab
Drug Alias NameZenoZenocutuzumab-ZBCOBizengriMCLA-128
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[6] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/04
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerus Nv
China Registration ClassN/A

Develop Information

Active CompaniesPartner Therapeutics IncGustave Roussy InstituteMerus Nv
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A